EP
CRBP icon

Eudaimonia Partners’s Corbus Pharmaceuticals CRBP Stock Holding History

Eudaimonia Partners’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-17
Closed -$1K – 563
2021
Q1 		$1K Buy
+17
New +$1.12K ﹤0.01% 1542

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Eudaimonia Partners's CRBP Position: Q2 2021 in Review

Eudaimonia Partners sold out of Corbus Pharmaceuticals (CRBP) in Q2 2021, closing a stake of 17 shares — an estimated $1K sold.

Eudaimonia Partners first reported a position in CRBP in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 98 funds tracked by Wall St. Rank hold CRBP as of Q2 2021.

  • Eudaimonia Partners reported no remaining Corbus Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 17 Corbus Pharmaceuticals shares in Q2 2021, an estimated $1K.
  • Eudaimonia Partners first reported a position in Corbus Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Eudaimonia Partners's Corbus Pharmaceuticals position peaked at $1K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.